Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1B | P36896 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | PAICS | P22234 | 3/20 | 0.37 |
| ▸ | ATM | Q13315 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4041629 | 0.91 | ACVR1B (0.41) | ACVR1BTGFBR1PAICSATMKDM4E | |
| SCHEMBL544971 | 0.89 | PAICS (0.38) | PAICSATMKDM4EMAPTMAPK1 | |
| SCHEMBL544621 | 0.88 | SLC6A9 (0.42) | PAICSATMKDM4EMAPTMAPK1 | |
| SCHEMBL544217 | 0.87 | KDM4E (0.41) | PAICSATMKDM4EMAPTMAPK1 | |
| SCHEMBL544620 | 0.85 | NOTUM (0.50) | KDM4ENOTUM | |
| SCHEMBL544260 | 0.84 | KDM4E (0.42) | PAICSATMKDM4EMAPTMAPK1 | |
| SCHEMBL544918 | 0.83 | PAICS (0.40) | PAICSATMKDM4EMAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL543957 | 0.81 | NTSR1 (0.40) | ACVR1BTGFBR1PAICSATMKDR | |
| Hydrochloric Acid SCHEMBL16493651 | 0.80 | ACVR1B (0.34) | ACVR1BTGFBR1PAICSATMKDM4E | |
| SCHEMBL4038154 | 0.79 | PAICS (0.39) | PAICSATMKDM4EMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552201-B2 | 5, 6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-20120108611-A1 | 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS | 2012-05-03 | — | — | US | disclosed |
| US-8110579-B2 | 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists | SANOFI-AVENTIS (FR) | 2012-02-07 | — | — | US | disclosed |
| US-20090318473-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI AVENTIS | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318473-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | ACVR1B 1754/4885TGFBR1 1698/4885PAICS 256/4885 |
| US-20120108611-A1 | 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | ACVR1B 1754/4885TGFBR1 1698/4885PAICS 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.